8 Key Partner Quality Attributes Your CDMO Must Have

By Pauline Ginsberg, PMP, Director of Project Management, INCOG BioPharma

Drug complexity, prevailing drug development economics, and speed to market are leading to an increasing reliance on contract manufacturers to span gaps in experience and capacity. As a result, demand for contract development and manufacturing (“CDMO”) services is rising rapidly. The biopharmaceutical fill finish manufacturing market was approximately $7.5 billion in 2020 and is projected to reach $12.1 billion by 2025 at compounded annual growth rate of 10% during the forecast period.¹

As a result of the rising demand for biotech innovations and pharmaceuticals, especially biologics and vaccines, it becomes easier to understand why many industry stakeholders engage CDMOs to help mitigate the complexity and costs associated with drug substance development and drug product manufacturing. Identifying the best CDMO with which to partner has become an integral component of many biopharma businesses. Their successful commercial drug development strategy depends on it.

This article shares eight key Partner Quality Attributes (PQAs) your CDMO partner should have.